Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

The company is expected to expand beyond its cystic fibrosis business ... in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals again raised its full-year outlook after posting earnings and revenue growth in the third quarter. The biotechnology company on Monday posted a quarterly net profit of $1.05 ...

So when a business like Vertex Pharmaceuticals (NASDAQ ... just a few months away from being approved for sale, it's a big development. On that note, let's dive in and investigate how the bull ...

Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering ... The firm focuses on development and commercializing therapies for the treatment ...

The company has also secured strategic partnerships with AstraZeneca for drug development and Ansys for engineering ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We are very pleased to have ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

M.D. Ph.D., 50 Northern Ave, Boston, Massachusetts 02210, Chief Scientific Officer, Executive Vice President, Global Research Vertex Pharmaceuticals Incorporated ...